BIO-key International, Inc. (BKYI) Income Statement
BKYI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBKYI revenue and net income
Where BKYI's revenue goes
2025Each bar shows an amount and its share of revenue. BKYI kept −75.3% of revenue as net income.
BKYI profit margins
BKYI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −12.0% | −4.6% | +16.5% | +1.5% |
| Gross profit | −16.3% | +1.0% | +18.3% | +1.7% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BKYI quarterly EPS vs estimates
BIO-key International beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 13, 2026 (estimate $-0.35).
BKYI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1M | $6.9M | $7.8M | $7.0M | $5.1M | $2.8M | $2.3M | $4.0M | $6.3M | $3.0M |
| Cost of revenue | $1.4M | $1.3M | $6.3M | $2.4M | $1.7M | $794,826 | $2.5M | $4.2M | $6.5M | $729,683 |
| Gross profit | $4.7M | $5.6M | $1.4M | $4.6M | $3.4M | $2.0M | −$193,717 | −$119,648 | −$181,318 | $2.2M |
| Research & development | $2.6M | $2.5M | $2.4M | $3.3M | $2.4M | $1.4M | $1.3M | $1.4M | $1.7M | $2.0M |
| Sales, general & admin | $6.3M | $7.1M | $8.5M | $9.6M | $6.0M | $5.8M | $5.0M | $5.3M | $5.7M | $4.4M |
| Total operating expenses | $9.0M | $9.7M | $10.3M | $14.5M | $8.4M | $7.2M | $13.3M | $6.7M | $7.3M | $6.4M |
| Operating income | −$4.3M | −$4.0M | −$8.8M | −$9.9M | −$4.9M | −$5.2M | −$13.5M | −$6.9M | −$4.3M | −$4.2M |
| Interest income | $3,787 | $110 | $5,961 | $233 | $4,075 | $30,649 | $154 | $80 | $27 | $30 |
| Interest expense | $317,626 | $299,755 | $218,270 | $10,462 | $18,000 | $4.3M | $1.1M | $80 | $27 | $30 |
| Income before taxes | −$4.6M | −$4.3M | −$8.7M | −$11.9M | −$5.1M | −$9.7M | −$14.6M | −$6.9M | −$4.3M | −$4.2M |
| Income taxes | −$16,500 | −$22,998 | −$134,014 | −$20,434 | −$496,073 | $3.9M | $64,281 | $160 | $0 | $912 |
| Net income | −$4.6M | −$4.3M | −$8.5M | −$11.9M | −$5.1M | −$9.7M | −$14.6M | −$6.9M | −$4.3M | −$4.2M |
| EBITDA | −$3.9M | −$3.5M | −$7.8M | −$11.4M | −$4.5M | −$4.9M | −$12.5M | −$5.1M | −$2.7M | −$4.1M |
| EPS (diluted) | −$6.94 | −$17.30 | −$85.20 | −$110.99 | −$48.59 | −$472.31 | −$341.48 | −$979.30 | −$863.94 | −$346.25 |
| Gross margin | 77.5% | 81.4% | 18.5% | 65.2% | 67.3% | 72.0% | −8.5% | −3.0% | −2.9% | 75.5% |
| Operating margin | −69.9% | −57.9% | −113.8% | −141.4% | −96.6% | −183.4% | −596.2% | −169.8% | −67.8% | −141.2% |
| Net margin | −75.3% | −62.1% | −109.9% | −169.7% | −99.0% | −341.0% | −643.4% | −169.8% | −67.8% | −140.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.1M | $1.2M | $1.5M | $1.7M | $1.6M | $1.5M | $2.1M | $1.1M | $2.2M | $2.3M | $1.8M |
| Cost of revenue | $245,951 | $376,300 | $271,371 | $357,988 | $464,180 | $279,498 | $262,360 | $465,110 | $262,272 | $299,643 | $4.4M | $1.5M |
| Gross profit | $1.7M | $1.8M | $969,974 | $1.2M | $1.2M | $1.3M | $1.2M | $1.7M | $879,014 | $1.9M | $2.3M | $340,504 |
| Research & development | $640,418 | $616,880 | $694,471 | $683,620 | $636,027 | $595,775 | $660,151 | $652,174 | $591,234 | $607,521 | $592,974 | $529,757 |
| Sales, general & admin | $1.6M | $1.3M | $1.8M | $1.4M | $1.7M | $1.4M | $1.8M | $1.6M | $1.9M | $1.9M | $2.4M | $1.6M |
| Total operating expenses | $2.2M | $1.9M | $2.6M | $2.1M | $2.3M | $2.0M | $2.7M | $2.3M | $2.5M | $2.4M | $2.5M | $2.3M |
| Operating income | −$529,405 | −$117,713 | −$1.6M | −$892,190 | −$1.1M | −$640,638 | −$1.3M | −$580,405 | −$1.7M | −$508,930 | −$200,510 | −$2.0M |
| Interest income | $386 | $675 | $1,177 | $515 | $2,092 | $3 | $57 | $2 | $46 | $5 | $5,589 | $3 |
| Interest expense | $27,000 | $27,166 | $122,904 | $13,174 | $25,638 | $35,910 | $66,932 | $98,556 | $12,910 | $1,356 | $58,891 | $45,655 |
| Income before taxes | −$576,852 | −$165,036 | −$1.7M | −$964,849 | −$1.2M | −$736,545 | −$1.4M | −$738,959 | −$1.7M | −$510,285 | −$6.4M | −$1.8M |
| Income taxes | — | $16,500 | $16,500 | — | — | −$22,998 | — | — | −$4 | −$276,825 | $4.1M | −$189 |
| Net income | −$576,852 | −$165,036 | −$1.7M | −$964,849 | −$1.2M | −$736,545 | −$1.4M | −$738,959 | −$1.7M | −$510,285 | −$4.1M | −$1.8M |
| EBITDA | −$434,453 | −$67,115 | −$1.5M | −$874,080 | −$1.0M | −$602,608 | — | −$415,984 | −$1.6M | −$407,116 | −$4.3M | −$1.7M |
| EPS (diluted) | −$0.56 | −$0.13 | — | −$1.49 | −$2.00 | −$1.45 | −$0.52 | −$3.90 | −$10.00 | −$2.88 | $0.00 | −$14.40 |
| Gross margin | 87.2% | 82.5% | 78.1% | 76.9% | 72.6% | 82.6% | 82.1% | 78.3% | 77.0% | 86.3% | 100.0% | 18.7% |
| Operating margin | −27.6% | −5.5% | −132.4% | −57.6% | −63.9% | −39.9% | −86.7% | −27.1% | −144.9% | −23.3% | −8.8% | −108.2% |
| Net margin | −30.0% | −7.7% | −138.7% | −62.3% | −68.8% | −45.8% | −94.7% | −34.5% | −146.1% | −23.4% | −180.6% | −101.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BKYI's financial statements (latest annual report filed June 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BKYI financial results
In fiscal year 2025 (ended December 31, 2025), BIO-key International reported revenue of $6.1 million, down 12.0% from the year before. It had a net loss of $4.6 million, a net profit margin of −75.3%. Diluted earnings per share came to −$6.94. Over five years revenue grew at an average rate of 16.5% a year.
See the BKYI stock overview for the latest quote and news, or the BKYI chart for price history and technical indicators.
BKYI income statement FAQ
What is BIO-key International's annual revenue?
BIO-key International reported total revenue of $6.1 million for fiscal year 2025, which ended on December 31, 2025. That was down 12.0% from $6.9 million the previous year.
Is BIO-key International profitable?
No. BIO-key International reported a net loss of $4.6 million in fiscal 2025, a net profit margin of −75.3%; its operating margin was −69.9%.
What is BIO-key International's gross margin?
BIO-key International's gross margin was 77.5% in fiscal 2025: for every $100 of revenue, BIO-key International kept $77 after the direct cost of its products and services.
How much does BIO-key International spend on research and development?
BIO-key International spent $2.6 million on research and development in fiscal 2025, 42.8% of revenue.
How fast is BIO-key International growing?
Revenue grew 16.5% a year on average over the last five fiscal years, from $2.8 million to $6.1 million.
What are BIO-key International's earnings per share?
BIO-key International earned $-6.94 per diluted share in fiscal 2025, compared with $-17.30 a year earlier.
When will BIO-key International report its next earnings?
BIO-key International is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does BIO-key International's fiscal year end?
BIO-key International's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on June 12, 2026.